ACM
BIO icon

Americafirst Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Americafirst Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,400
Closed -$255K – 167
2016
Q4 		$255K Sell
1,400
-9,360
-87% -$1.6M 0.27% 109
2016
Q3 		$1.76M Buy
+10,760
New +$1.63M 1.46% 14
2015
Q1 		– Sell
-5,135
Closed -$619M – 262
2014
Q4 		$619M Buy
+5,135
New +$591K 0.3% 100

Other funds holding BIO

ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Americafirst Capital Management's BIO Position: Q1 2017 in Review

Americafirst Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2017, closing a stake of 1,400 shares — an estimated $255K sold.

Americafirst Capital Management first reported a position in BIO in Q4 2014 and held it in 3 quarters. The position peaked at $619M in Q4 2014. 274 funds tracked by Wall St. Rank hold BIO as of Q1 2017.

  • Americafirst Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2017 after selling out during the quarter.
  • Americafirst Capital Management sold 1,400 Bio-Rad Laboratories Class A shares in Q1 2017, an estimated $255K.
  • Americafirst Capital Management first reported a position in Bio-Rad Laboratories Class A in Q4 2014 and held it in 3 quarters.
  • Americafirst Capital Management's Bio-Rad Laboratories Class A position peaked at $619M in Q4 2014.
  • 274 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2017.

Based on Americafirst Capital Management's 13F filing for Q1 2017, filed 17 Apr 2017.